Abstract: The present invention provides pharmaceutically acceptable and ophthalmologically suitable compositions comprising a therapeutically effective amount of a bimatoprost compound, a therapeutically effective amount of a timolol compound, benzalkonium chloride, and a penetration enhancer component other than benzalkonium chloride. In specific embodiments, compositions are provided as aqueous solutions. Further, in aspects, the invention also provides a process of preparing such compositions and methods of their use in treating ocular conditions, such as methods of reducing elevated intraocular pressure and/or treating glaucoma, such as open-angle glaucoma.
Type:
Grant
Filed:
March 21, 2023
Date of Patent:
July 23, 2024
Assignee:
SOMERSET THERAPEUTICS, LLC
Inventors:
Mandar V. Shah, Veerappan Subramanian, Ilango Subramanian, Aman Trehan
Abstract: The present disclosure is directed at compositions of dimethyl trisulfide (DMTS) suitable for use for treatment of cyanide intoxication. The compositions show particularly useful stability such that the DMTS remains stable for therapeutic use at the identified time periods. The compositions are therefore particularly suitable for use in autoinjectors.
Abstract: The present application provides processes for preparing (R)-4-(3-((S)-1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one, which is useful as an inhibitor phosphoinositide 3-kinase-delta (PI3K?), as well as a salt form and intermediates related thereto.
Inventors:
Lei Qiao, Lingkai Weng, Chongsheng Eric Shi, David Meloni, Qiyan Lin, Michael Xia, Vaqar Sharief, William Frietze, Zhongjiang Jia, Yongchun Pan, Pingli Liu, Tai-Yuen Yue, Jiacheng Zhou, Jianji Wang
Abstract: The present invention relates to methods for treating uterine hypercontractility disorders. in particular, the present invention relates to methods for treating abnormal uterine bleeding and dysmenorrhea comprising administering to women suffering from such disorders a pharmaceutical composition comprising an S-alkylisothiouronium derivative.
Abstract: Disclosed are an abietane type diterpene compound, a preparation method and an application thereof, relating to the technical field of anti-tumor compounds, where the compound has a chemical structure as shown in the following formula I: Leucosceptrum canum is extracted to prepare the abietane type diterpene compound according to the present application, and the prepared compound is effectively applied in inhibiting human lung cancer cell A549 and human myeloid leukemia cell HL-60.
Abstract: The inventors have used a differential nuclear staining (DNS) assay to discover compounds with cytotoxic activity against the CEM cell line that has been determined to be highly sensitive to a variety of anti-cancer compounds. Compounds were synthesized based on a pyrazole backbone structure. Several newly synthesized compounds have been tested to identify the compounds with highest activity. One compound identified is the SSK-3 compound which has been tested on cancer cell lines and determined that it induced apoptosis via phosphatidylserine membrane exposure and activation of caspase 3 in the CEM lymphoma cell line.
Type:
Grant
Filed:
October 12, 2022
Date of Patent:
May 14, 2024
Assignees:
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Inventors:
Renato J. Aguilera, Subhas S. Karki, Sujeet Kumar, Manuel L. Penichet
Abstract: Provided herein are methods of enhancing mechanical thrombectomy during endovascular therapy for acute thrombosis using 3,3?-diindolylmethane.
Abstract: Simultaneous inhibition of the aryl hydrocarbon receptor (AhR) and SRC abolishing androgen receptor (AR) signaling in prostate cancer cells is disclosed herein as an effective treatment for prostate cancer. Provided herein is a therapeutic composition that comprises an aryl hydrocarbon receptor (AhR) antagonist and an SRC inhibitor. In one embodiment, the therapeutic composition further comprises a pharmaceutical excipient. In one embodiment, the AhR antagonist is CH223191 and the SRC inhibitor is PP2 and the therapeutic composition further comprises a pharmaceutical excipient. Methods of using the therapeutic composition to treat prostate cancer or to inhibit prostate cancer cells are also disclosed.
Abstract: This invention relates to the treatment of Pulmonary Hypertension with heart failure with preserved ejection fraction (PH-HFpEF). More specifically, embodiments of the invention provide compositions and methods useful for the treatment of PH-HFpEF employing the use of levosimendan.
Type:
Grant
Filed:
December 15, 2020
Date of Patent:
April 30, 2024
Assignee:
TENAX THERAPEUTICS, INC.
Inventors:
Stuart Rich, Douglas Randall, Douglas Hay
Abstract: A imine Ru(III) complex based on 4-Aminobenzene Sodium Sulphonate, its synthesis, and its use for pharmaceutical applications.
Type:
Grant
Filed:
December 5, 2023
Date of Patent:
April 30, 2024
Assignee:
KING FAISAL UNIVERSITY
Inventors:
Mai Mostafa Khalaf Ali, Hany Mohamed Abd El-Lateef Ahmed, Mohamed Gouda, Asmaa Ebrahim Hassan, Mosa Alsehli, Eida S Al-Farraj, Ahmed M. Abu-Dief
Abstract: The present disclosure describes methods of treating a central nervous system condition associated with oxidative stress using a 5-lipoxigenase activating protein (FLAP) inhibitor, for example, N-acetylcysteine or nordihydroguaiaretic acid. The present disclosure also describes methods of treating a central nervous system condition with N-acetylcysteine and a second therapeutic agent such as prostaglandin E2.
Type:
Grant
Filed:
January 13, 2023
Date of Patent:
April 23, 2024
Assignees:
Neuronasal, Inc., Burke Neurological Institute
Inventors:
Rajiv R. Ratan, Saravanan Karuppagounder, Thomas I. Bradshaw
Abstract: A combination composition including as active components, in synergistically effective amounts of (i) a steroidal saponin of natural or synthetic origin, a pharmaceutical acceptable salt thereof or a plant extract containing steroidal saponin, and (ii) at least a first polyphenolic compound selected from the group of hydroxycinnamic acids, flavonoids, hydroxybenzoic acids, and (iii) optionally, a second polyphenolic compound, wherein the second polyphenolic compound is hydroxycinnamic acids and its use in preventing, inhibiting, retarding or treating a subject suffering from a neurodegenerative disease or condition.
Abstract: Provided herein are methods for treating sickle cell disease, comprising administering to a subject 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)-methoxy)benzaldehyde (Compound 1), or a polymorph thereof, in certain dosing regimens.
Type:
Grant
Filed:
August 5, 2022
Date of Patent:
April 2, 2024
Assignee:
Global Blood Therapeutics, Inc.
Inventors:
Eleanor L. Ramos, Joshua Eli Lehrer-Graiwer, Athiwat Hutchaleelaha, Naveen Bejugam
Abstract: Disclosed herein are compositions and methods for delivering compositions to a subject in need of treatment for epilepsy. The disclosed compositions are orally delivered. Further disclosed are kits comprising the disclosed compositions as part of a method of delivering cannabidiol and CBD-containing compositions to subjects in need of treatment for epilepsy.
Type:
Grant
Filed:
July 24, 2023
Date of Patent:
April 2, 2024
Assignee:
POVIVA CORP
Inventors:
John Docherty, Christopher Andrew Bunka
Abstract: The present disclosure relates to compounds of Formula (Ia) and (Ib): or a pharmaceutically acceptable salt thereof, which are useful in the treatment of an HIV infection in heavily treatment-experienced patients with multidrug resistant HIV infection.
Type:
Grant
Filed:
July 15, 2019
Date of Patent:
April 2, 2024
Assignee:
Gilead Sciences, Inc.
Inventors:
Laura Elizabeth Bauer, Anna Chiu, Eric M. Gorman, Andrew Stephen Mulato, Martin Sunkwang Rhee, Charles William Rowe, Scott P. Sellers, Dimitrios Stefanidis, Winston C. Tse, Stephen R. Yant, Dana J. Levine
Abstract: The present invention relates to pharmaceutical compositions comprising a compound of Formula (I) that are useful for the intramuscular delivery of antipsychotic drugs using rapid injection rates.
Abstract: Provided herein are methods of administering to a peroneal and a tibial nerve of a patient, wherein the methods include: (a) selecting an entry point of an injection needle in a leg of a patient; (b) inserting the injection needle into the patient at the entry point; (c) administering to a sciatic nerve of the patient via the injection needle saline and a pharmaceutical composition; wherein the pharmaceutical composition comprises multivesicular liposomes comprising: at least one amphipathic lipid, at least one neutral lipid, and bupivacaine phosphate, wherein the bupivacaine phosphate is encapsulated within the multivesicular liposome.
Abstract: The invention relates to vascular disrupting agent (VDA) such as combretastatins for treating avascular or hypovascular micro-tumors with a diameter below 20 mm.
Abstract: The present invention relates to a pidolate salt and malate salt of a compound represented by a formula 1 with an excellent liquid-phase stability, solid-phase stability, water solubility, precipitation stability and hygroscopicity all together as a compound for preventing and treating diseases mediated by an acid pump antagonistic activity, as well as a method for preparing the same.
Type:
Grant
Filed:
November 21, 2022
Date of Patent:
February 27, 2024
Assignee:
HK INNO.N CORPORATION
Inventors:
Eun Sun Kim, Min Kyoung Lee, Sung Ah Lee, Kwang Do Choi, Jae Sun Kim, Hyung Chul Yoo
Abstract: The present invention relates to a liquid pharmaceutical formulation of hypoglycaemic sulfonamide, intended for oral or ophthalmic administration. The present invention relates in particular to an oral formulation particularly suitable for paediatric use.